Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease;Documento de consenso en el uso de la granulocitoaféresis en pacientes con enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 29, Issue 2, 2006, Pages 85-92

  Cabriada, J L ^a   Domenech E ^b   Gomollon F ^c   Gonzalez Carro P ^d   Gonzalez Lara V ^e   Hinojosa, J ^f   Jimenez Lopez C E ^g   Nos, P ^h   Obrador, A ⁱ   Panes J ^j   Saro, C ^k   Varea, V ^l   Lafuente, R ^m   Guilera, M ^n,o  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL DE SAGUNTO   (Spain)

^g Universidad Pública de Navarra   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL DE CABUEÑES   (Spain)

^l HOSPITAL SANT JOAN DE DÉU   (Spain)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ HOR Europe   (Spain)

^o Health Outcomes Research Europe   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

CONSENSUS DEVELOPMENT; CROHN DISEASE; ENTERITIS; HUMAN; LEUKAPHERESIS; PRACTICE GUIDELINE; PREGNANCY; REMISSION; REVIEW; RISK ASSESSMENT; ULCERATIVE COLITIS;

EID: 33644556880     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083905     Document Type: Article

References (40)

1. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:21-33.
2. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489-93.
3. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology. 1978;74:501-3.
4. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994;35:669-74.
5. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol. 2003;98:511-2.
6. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut. 1998;42:470-6.
7. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-98.
8. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994;106:533-9.
9. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
10. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97:2820-8.
11. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprolectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-4.
12. Charron M, Del Rosario JF, Kocoshis S. Use of technetium-tagged white blood cells in patients with Crohn's disease and ulcerative colitis: is differential diagnosis possible? Pediatr Radiol. 1998;28:871-7.
13. Otsuka Pharmaceuticals. Adacolumn apheresis treatment in patients with immune disorders: rationale and summary of results. Reino Unido: Otsuka Pharmaceuticals, 2005.
14. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48-59.
15. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565-71.
16. Shimoyama T, Sawada Y, Onishi K, Egashira A, Kaneda M, Hida N, et al. Leukocyte adsorption and removal for the treatment of ulcerative colitis. Nippon Naika Gakkai Zasshi. 1999;88:724-30.
17. Suzuki Y, Yoshimura N, Saitoh Y, Saniabadi AR. Granulocyte and monocyte adsorptive apheresis in a case with severe ulcerative colitis unresponsive to conventional medication. J Clin Apheresis. 2003;18:40-2.
18. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20:783-92.
19. Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-52.
20. Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci. 2002;47:2349-53.
21. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334-41.
22. Shimoyama T, Sawada Y, Hiwatashi N, Sawada T, Saniabadi AR. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001;16:1-9.
23. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48-59.
24. Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs. 1997;21:989-94.
25. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004;99:1532-8.
26. Tabuchi T, Ubukata H, Saniabadi AR, Soma T. Granulocyte apheresis as a possible new approach in cancer therapy: a pilot study involving two cases. Cancer Detect Prev. 1999;23:417-21.
27. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher. 1998;2:134-41.
28. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
29. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251-7.
30. Shimoyama T, Sawada Y, Tanaka T, Saito Y, Munakata A, Toyoda T. Granulocytapheresis in active ulcerative colitis. A multicenter randomized study. Jpn J Apher. 1999;18:117-31.
31. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis. 2001;16:1-9.
32. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44.
33. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:811-7.
34. Cuenca F, Garcia PJ, Mendoza JL, Cruz DM, Herrero A, Díaz-Rubio M. Experiencia con la agranulocitoaféresis en la enfermedad de Crohn. Rev Esp Enferm Dig. 2004;96:501-6.
35. Kirschner BS. The medical management of inflammatory bowel disease in children. En: Kirsner JB, editor. Inflammatory bowel disease. Philadelphia: WB Saunders; 2000. p. 578-97.
36. Saha MT, Ruuska T, Laippala P, Lenko HL. Growth of prepubertal children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;26:310-4.
37. Berger M, Gribetz D, Korelitz BI. Growth retardation in children with ulcerative colitis: the effect of medical and surgical therapy. Pediatrics. 1975;55:459-67.
38. Martín de Carpi J, Varea V, Vilar P, Ribes C, García Novo M, Prieto G. Leukocite adsorptive apheresis in paediatric inflammatory bowel disease: safety and tolerance of the technique and preliminary data of efficacy. J Pediatr Gastroenterol Nutr. 2004;39:S315-6.
39. Tomomasa T, Kobayashi A, Kaneko H, Mika S, Maisawa S, Chino Y, et al. Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 2003;48:750-4.
40. Esteve-Comas M, Gassull MA. Corticorresistencia y corticodependencia en la enfermedad inflamatoria intestinal. En: Esteve-Comas M, Gassull MA, editores. Enfermedad inflamatoria intestinal. Madrid: Ergon; 2002.